[
  {
    "text": "immediately prior thereto ceasing to represent, or being converted into or exchanged for voting securities that do not represent, at",
    "bbox": [
      114,
      98,
      1000,
      110
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "least fifty percent (50%) of the combined voting power of the voting securities of the surviving entity or the parent corporation of",
    "bbox": [
      113,
      117,
      1000,
      130
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "the surviving entity immediately after such merger, reorganization or consolidation, (b) a transaction in which a Third Party becomes",
    "bbox": [
      112,
      135,
      1000,
      149
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of PB, other than",
    "bbox": [
      113,
      155,
      1000,
      167
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "through the issuance of voting securities for the purpose of raising financing to one or more financial or institutional investors that",
    "bbox": [
      111,
      172,
      1000,
      187
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "are not then controlled by an entity engaged in the development or commercialization of pharmaceutical or biotechnology products.",
    "bbox": [
      113,
      193,
      1000,
      206
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "or (c) the sale or other transfer of all or substantially all of PB's business or assets relating to the Product for use in the Indication.",
    "bbox": [
      113,
      211,
      1000,
      224
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "A Licensing Transaction shall not constitute a Change of Control, unless such Licensing Transaction includes the grant of US",
    "bbox": [
      114,
      231,
      1000,
      243
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Commercialization Rights in which event such Licensing Transaction shall be deemed to be a Change in Control.",
    "bbox": [
      112,
      249,
      1000,
      263
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.26 \"Change of Control Buy-Out Payment' has the meaning ascribed to such term in Section 6.7.2",
    "bbox": [
      249,
      284,
      1000,
      296
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.27 \"Claim\"' means any Third Party claim, demand, suit and/or cause of action..",
    "bbox": [
      247,
      319,
      936,
      333
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.28 \"Clinical Investigator' means the principal investigator at each Site..",
    "bbox": [
      249,
      356,
      869,
      370
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.29 \"Clinical Investigator Meeting\"' has the meaning ascribed to such term in Section 3.2.2.1.",
    "bbox": [
      247,
      390,
      1000,
      406
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.30 \"Clinical Supply Agreement\" has the meaning ascribed to such term in Section 3.14.1.2..",
    "bbox": [
      249,
      428,
      1000,
      441
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.31 \"Clinical Supply Agreement' has the meaning ascribed to such term in Section 3.14.1.1..",
    "bbox": [
      248,
      463,
      1000,
      478
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.32 \"Clinical Trials\"' means the Phase 3 Trial, any required supplemental clinical trial of the Product in China",
    "bbox": [
      248,
      500,
      1000,
      514
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "contemplated by the Development Plan, and the pharmacokinetic study of the Product in Japanese Subjects contemplated by the",
    "bbox": [
      114,
      521,
      1000,
      533
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Development Plan.",
    "bbox": [
      113,
      540,
      272,
      552
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.33 \"Clinical Trial Activity\"' has the meaning ascribed to such term in Section 2.3.1.",
    "bbox": [
      248,
      573,
      973,
      587
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.34 \"Clinical Trial Agreement' has the meaning ascribed to such term in Section 3.2.1.3..",
    "bbox": [
      249,
      609,
      1000,
      623
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.35 \"Clinical Trials Database\"' has the meaning ascribed to such term in Section 3.5.3.1..",
    "bbox": [
      248,
      645,
      1000,
      659
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1.36 \"Clinical Trials Master File' has the meaning ascribed to such term in Section 3.5.4..",
    "bbox": [
      247,
      681,
      1000,
      695
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
    "bbox": [
      133,
      1000,
      621,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  }
]